Bharat Biotech begins Phase-III trials for COVID-19 vaccine, Covaxin, with 26,000 volunteers

"This is India's first phase-III efficacy study for a Covid-19 vaccine, and the largest phase-III efficacy trial ever conducted in India," said Bharat Biotech in a statement on Monday, adding that the trial was registered at ICMR and approved by the Drugs Controller General of India.
Source: The Economic Times Healthcare and Biotech News - Category: Pharmaceuticals Source Type: news